Maxpar® Direct™ Immune Profiling Assay™
The Maxpar Direct Immune Profiling Assay™ sets a new standard for comprehensive immunophenotyping of human PBMC and whole blood by enabling simultaneous identification and enumeration of 37 immune cell subsets. 30 markers. 1 tube. 5-minute data analysis.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The Maxpar® Direct™ Immune Profiling System is the first complete sample-to-answer solution for high-dimensional immune profiling of human PBMC and whole blood.
Designed as a simple single-tube workflow, the system brings together CyTOF® technology on the Helios™ system, a dry 30-marker antibody panel and automated Maxpar Pathsetter™ software so you can easily count 37 immune cell populations with performance you can trust.
Comprehensive
Profile 37 immune cell populations from PBMC or whole blood with an optimized 30-marker panel.
Efficient
Simple single-tube workflow with pushbutton reporting. Just add sample and go.
Reliable
Produce consistent results lot-to-lot, run-to-run and site-to-site.
The highly multiplexed 30-marker antibody panel was developed with input from expert immunologists in academia and biopharma and builds on the panels designed by the Human ImmunoPhenotyping Consortium (Maecker, H.T. et al. “Standardizing immunophenotyping for the Human Immunology Project.” Nature Reviews Immunology 12 (2012): 191–200.).
Designed using industry-proven antibody clones, this assay provides you with the broadest single-tube view of the immune system from each precious sample.
You no longer need to compromise your study design due to the limitations of fluorescence cytometry.
Integrated platforms for immunotherapy research and biomarker analysis
Immunotherapy has transformed cancer treatment but 60-70% of patients still fail to respond to these treatments. The challenge lies in accurately identifying which patients will benefit from these therapies due to inadequate predictive biomarkers. However, the solution to this extends far beyond simply identifying more biomarkers.
Addressing existing challenges requires integrated platforms that maintain analytical depth while providing the standardization, throughput, and regulatory compliance needed for clinical implementation. Standard Biotools has developed advanced immune profiling technologies that simultaneously capture functional states, rare cell populations, and spatial relationships to help identify predictive biomarkers for immunotherapy response.
Download this SelectScience guide to explore how to:
- Reveal hidden biomarkers via functional immune profiling
- Scale discovery to clinical reality
- Capture spatial context and dynamic range
- Integrate transcriptomics and proteomics
Resource details:
- Document type: SelectScience guide
- Page count: 40
- Read time: 60 mins
- Edition: 1st
Assay validation processes to ensure accuracy and precision in immune profiling
Explore validation testing on the Maxpar Direct Immune Profiling Assay panel that confirms high reproducibility across multiple sites, high repeatability across sample types, including whole blood and PBMC, and robust intermediate precision when used by different technicians.
How imaging mass cytometry technology uniquely detects low-abundance biomarkers
This technical note outlines why the high dynamic range of IMC technology is critical for protein quantification and enables the assessment of expression level without saturation of signals. It also outlines the significance of detecting low-level marker expression (highlighting PD-1, PD-L1 and CTLA-4); how IMC technology allows for clear analysis of low-abundance markers, and examples of PD-1, PD-L1 and CTLA-4 marker expression analysis using IMC systems.
